We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
Cap. Flow
-$79.9M
Cap. Flow %
-0.68%
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$208M
2
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$109M
3
BMY icon
Bristol-Myers Squibb
BMY
+$74.8M
4
BLUE
bluebird bio
BLUE
+$56.1M
5
CAH icon
Cardinal Health
CAH
+$54.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$191M
2
AGN
Allergan Inc
AGN
+$158M
3
MRK icon
Merck
MRK
+$149M
4
BIIB icon
Biogen
BIIB
+$113M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$106M

Sector Composition

Rank Sector Weight
1 Healthcare 83.37%
2 Technology 0.15%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UPI
126
DELISTED
UROPLASTY INC-NEW
UPI
$1.66M 0.01%
1,363,500
– –
ACHN
127
DELISTED
Achillion Pharmaceuticals
ACHN
$1.56M 0.01%
158,000
– –
AMRN
128
Amarin Corp
AMRN
$300M
$819K 0.01%
17,500
-2,500
-13% -$76.4K
AGEN
129
Agenus
AGEN
$279M
– –
-124,394
Closed -$9.69M
ELV icon
130
Elevance Health
ELV
$82.3B
– –
-138,800
Closed -$17.4M
MDT icon
131
Medtronic
MDT
$112B
– –
-493,800
Closed -$37.4M
LITS
132
Lite Strategy Inc
LITS
$32.4M
– –
-121,225
Closed -$10.4M
NSPR icon
133
InspireMD
NSPR
$31.6M
– –
0
– -$2.45M
RGLS
134
DELISTED
Regulus Therapeutics
RGLS
– –
-3,333
Closed -$6.42M
SGMO
135
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-100,000
Closed -$1.52M
SPY icon
136
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-200,000
Closed -$41.1M
XOMA
137
DELISTED
Xoma
XOMA
– –
-100,000
Closed -$7.18M
LUMO
138
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-11,111
Closed -$3.98M
SGEN
139
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,000
Closed -$3.21M
ALBO
140
DELISTED
Albireo Pharma Inc
ALBO
– –
-6,990
Closed -$279K
STJ
141
DELISTED
St Jude Medical
STJ
– –
-173,000
Closed -$11.3M
AEGR
142
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-400,000
Closed -$8.38M
GEVA
143
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-77,800
Closed -$7.22M
NPSP
144
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-2,954,900
Closed -$106M
COV
145
CALL
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-250,000
Closed -$25.6M
COV
146
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-211,200
Closed -$21.6M
SHPG
147
CALL
DELISTED
Shire pic
SHPG
– –
-50,000
Closed -$10.6M
AGN
148
CALL
DELISTED
Allergan Inc
AGN
– –
-250,000
Closed -$53.1M
AGN
149
DELISTED
Allergan Inc
AGN
– –
-741,300
Closed -$158M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2015 Portfolio in Review

As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
  • OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
  • OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
  • OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
  • OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
  • OrbiMed opened 27 new positions and closed 20 in Q1 2015.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.